Company profile
Juno Therapeutics, Inc.
Privately held: no public share price (Same real-world entity as "Juno Therapeutics, Inc., a Bristol-Myers Squibb Company" above (Celgene-era sponsor-name variant, pre-dating Celgene's 2019 acquisition by BMS); canonical_name intentionally matched so both resolve to one company row. Sources: https://clinicaltrials.gov/study/NCT03430011 Entity resolved by asset-pipeline-v2.)
Assets
(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | GPRC5DCell therapy | Multiple Myeloma |
Upcoming events
Research
Sign in to access ResearchUnlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Research
Sign in to access ResearchUnlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.